Abstracts tagged "Cutaneous"

Abstract Number: 0598 • ACR Convergence 2021
Differences in Discoid Lupus Erythematosus Skin Lesion Distribution and Characteristics in Black and Non-Black Patients: A Retrospective Cohort Study
Adrienne Joseph, Brandon Windsor, Linda Hynan and Benjamin Chong, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Epidemiological studies have shown that discoid lupus erythematosus (DLE) has a higher incidence and prevalence in minorities, particularly Black individuals. Racial differences in clinical…
Abstract Number: 0970 • ACR Convergence 2021
Hippo Signaling Is a Novel Regulator of Apoptosis and Photosensitivity in Lupus Keratinocytes
Grace Hile¹, Patrick Coit², Bin Xu¹, Shannon Estadt¹, Jacob Martens³, Rachael Wasikowski¹, Lam Tsoi¹, Ramiro Iglesias-Bartolome⁴, Celine Berthier¹, Allison Billi⁵, Johann Gudjonsson⁵, Amr Sawalha² and J. Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²University of Pittsburgh, Pittsburgh, PA, ³Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, ⁴NIH, National Cancer Institute, Bethesda, MD, ⁵Department of Dermatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Skin inflammation and photosensitivity are common manifestations of cutaneous (CLE) and systemic lupus erythematosus (SLE), yet the mechanisms underlying heightened cell death and epidermal…
Abstract Number: 1043 • ACR Convergence 2021
Prevalence of Multimorbidity in Cutaneous Lupus Erythematosus: A Population-Based Study
Mehmet Hocaoglu¹, Mark Davis², Maria Valenzuela-Almada³, Jesse Dabit², Shirley-Ann Osei-Onomah², Sebastian Vallejo-Ramos², Tina Gunderson², Kurt Greenlund⁴, Kamil Barbour⁴, Cynthia Crowson⁵ and Ali Duarte-Garcia², ¹University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ²Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Centers for Disease Control, Atlanta, GA, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Cutaneous lupus erythematosus (CLE) patients report impaired quality of life due to cutaneous and psychological morbidity. Previous literature on the prevalence of comorbidities in…
Abstract Number: 1282 • ACR Convergence 2021
Classification of Disease Activity and Damage in Cutaneous Lupus
Laila Abbas, Karabi Nandy and Benjamin Chong, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The Cutaneous Lupus Disease Area and Severity Index (CLASI) can quantify disease activity and damage in Cutaneous Lupus Erythematosus (CLE). Classification of CLASI scores…
Abstract Number: 1491 • ACR Convergence 2021
Single-cell Analysis of Paired Skin and Blood Samples from Patients with SLE and Cutaneous Lupus Suggests CD16+ DCs Arise from Non-classical Monocytes That Enter Nonlesional Skin, Undergo Type I IFN Education, and Engage in Extensive Crosstalk with Diverse Immune and Stromal Cell Types
Allison Billi¹, Feiyang Ma², Olesya Plazyo³, Grace Hile³, Xianying Xing³, Mehrnaz Gharaee-Kermani⁴, Rachael Wasikowski³, Lam Tsoi³, Matteo Pellegrini², Robert L. Modlin², Johann Gudjonsson¹ and J. Michelle Kahlenberg³, ¹Department of Dermatology, University of Michigan, Ann Arbor, MI, ²University of California Los Angeles, Los Angeles, CA, ³University of Michigan, Ann Arbor, MI, ⁴Internal Medicine - Division of Rheumatology and Department of Dermatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Cutaneous lupus erythematosus (CLE) is an incompletely understood autoimmune disease that can occur in isolation or in the context of SLE. CLE is often…
Abstract Number: 1495 • ACR Convergence 2021
Multiplexed Profiling of Treatment Naïve Cutaneous Lupus Skin Stratified by Patient Response to Antimalarials
Thomas Vazquez¹, Jay Patel², Daisy Yan³, Emily Keyes⁴, DeAnna Diaz⁵, Yubin Li⁶, Madison Grinnell⁶, Rui Feng⁷ and Victoria Werth³, ¹FIU Wertheim College of Medicine, Virginia Beach, VA, ²Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, NJ, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ⁵Philadelphia College of Medicine, Philadelphia, PA, ⁶Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, PA, ⁷University of Pennsylvania Department of Biostatistics, Philadelphia, PA
Background/Purpose: Lupus erythematous (LE) is a systemic autoimmune disease with a variety of cutaneous manifestations. Antimalarials are first-line systemic therapy, yet not all patients respond…
Abstract Number: 0278 • ACR Convergence 2020
Trends in Incidence of Cutaneous Lupus Erythematosus from 1976 to 2018: A Population-Based Study
Mehmet Hocaoglu¹, Mark Denis P. Davis², Shirley-Ann Osei-Onomah³, Jesse Dabit², Rachel Giblon², Thomas O'Byrne², Cynthia Crowson⁴ and Ali Duarte-Garcia², ¹University of Maryland Medical Center Midtown Campus, Baltimore, MD, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a heterogeneous chronic disease with potential for long lasting morbidity. Studies that provide incidence data on the entire spectrum…
Abstract Number: 0300 • ACR Convergence 2020
Exposure to Topical Antimicrobials Reduces Inflammatory Gene Expression in Cutaneous Lupus Lesional Skin
Sirisha Sirobhushanam¹, Allison Billi², Alex Tsoi², Celine Berthier², Johann Gudjonsson³ and J. Michelle Kahlenberg⁴, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³University of Michigan, Ann ArborUniversity of Michigan, ⁴Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Lupus lesional skin has elevated interferon expression, is highly colonized with Staphylococcus aureus (50%) and has no FDA-approved treatment options. S. aureus is known…
Abstract Number: 0985 • ACR Convergence 2020
Early and Sustained Reduction in Severity of Skin Disease with Anifrolumab Treatment in Patients with Active SLE Measured by the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI): Pooled Data from 2 Phase 3 Studies
Victoria Werth¹, Richard Furie², Eric Morand³, J. Michelle Kahlenberg⁴, Rubana Kalyani⁵, Gabriel Abreu⁶, Lilia Pineda⁵ and Raj Tummala⁵, ¹University of Pennsylvania and Corporal Michael J. Crescenz Veterans Administration Hospital, Philadelphia, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, ³Monash University, Melbourne, Australia, ⁴Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: Up to 85% of patients with SLE experience skin disease.1 The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated index…
Abstract Number: 0986 • ACR Convergence 2020
BIIB059, a Humanized Monoclonal Antibody Targeting Blood Dendritic Cell Antigen 2 on Plasmacytoid Dendritic Cells, Shows Dose-Related Efficacy in a Phase 2 Study in Participants with Active Cutaneous Lupus Erythematosus
Victoria Werth¹, Richard Furie², Juanita Romero-Díaz³, Sandra Navarra⁴, Kenneth Kalunian⁵, Ronald van Vollenhoven⁶, Filippa Nyberg⁷, Benjamin Kaffenberger⁸, Saira Sheikh⁹, Goran Radunovic¹⁰, Xiaobi Huang¹¹, Hua Carroll¹², Francois Gaudreault¹², Adam Meyers¹¹, Catherine Barbey¹³, Cristina Musselli¹¹ and Nathalie Franchimont¹¹, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁴University of Santo Tomas, Manila, Philippines, ⁵University of California San Diego, La Jolla, CA, ⁶Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁷Karolinska University Hospital, Stockholm, Sweden, ⁸Ohio State University, Columbus, OH, ⁹Division of Rheumatology, Allergy and Immunology, University of North Carolina, Chapel Hill, NC, ¹⁰Institute of Rheumatology, University of Belgrade, Belgrade, Serbia, ¹¹Biogen, Cambridge, MA, ¹²Biogen, Cambridge, ¹³Biogen, Baar, Switzerland
Background/Purpose: No approved targeted therapies have been developed for cutaneous lupus erythematosus (CLE), a disfiguring autoimmune disease that severely impairs quality of life.1 BIIB059 is…
Abstract Number: 1065 • ACR Convergence 2020
Immunostimulatory Herbal Supplement Use Is More Common Among Patients with Dermatomyositis
Adarsh Ravishankar¹, Daisy Yan², Christina Bax³, Josef Symon Concha², Bridget Shields⁴, Lisa Pappas-Taffer⁴, Rui Feng⁵, Joyce Okawa⁴ and Victoria Werth², ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ²University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ³University of Pennsylvania, Department of Dermatology, Philadelphia, ⁴Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia
Background/Purpose: The use of complementary and alternative medicine (CAM) is prevalent in dermatology. Certain CAMs, including Spirulina, Alfalfa, Chlorella, Echinacea, and Blue-Green Algae have been…
Abstract Number: 1982 • ACR Convergence 2020
Quality of Life of Patients with Facial Cutaneous Lupus Erythematosus
Josef Symon Concha¹, Daisy Yan¹, Christina Bax², Adarsh Ravishankar³, Robert Borucki⁴, Rui Feng⁴ and Victoria Werth⁵, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²University of Pennsylvania, Department of Dermatology, Philadelphia, ³University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ⁴University of Pennsylvania, Philadelphia, ⁵University of Pennsylvania and Corporal Michael J. Crescenz Veterans Administration Hospital, Philadelphia
Background/Purpose: Cutaneous Lupus Erythematosus (CLE) is an autoimmune skin disease that may occur with or without systemic lupus erythematosus (SLE). Active CLE lesions present with…
Abstract Number: 1989 • ACR Convergence 2020
NXP2 Autoantibodies Link to Interferon Signature in Juvenile Myositis Lesional Skin
Jessica Turnier¹, Lauren Pachman², Lori Lowe³, Alex Tsoi³, Sultan Elhaj¹, Rajasree Menon¹, Maria Amoruso², Gabrielle Morgan⁴, Johann Gudjonsson⁵, Celine Berthier³ and J Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³University of Michigan, Ann Arbor, ⁴Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵University of Michigan, Ann ArborUniversity of Michigan
Background/Purpose: Skin inflammation can herald systemic disease in juvenile myositis (JM), yet we lack an understanding of pathogenic mechanisms driving skin inflammation in JM. The…